Navidea Biopharmaceuticals to Co-Sponsor Alzheimer’s Imaging Consortium at Alzheimer’s Association International Conference
Educational sessions will focus on clinical application and development of neuroimaging to Alzheimers disease and dementia
DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that it will co-sponsor the 2013 Alzheimers Imaging Consortium on July 13, 2013. The full-day event features leading international experts and will be chaired by Drs. Gil Rabinovici, University of California, San Francisco, United States, and Christopher Rowe, Austin Health, Melbourne, Australia. The Consortium is part of the Alzheimers Association International Conference (AAIC), being held July 13 18, 2013, in Boston, Mass. The annual AAIC is attended by leaders in dementia research and medicine from around the globe, and is the largest conference of its kind in the world.
We are honored that Navidea is supporting the Alzheimers Imaging Consortium, because education and peer-to-peer scientific dialogue are fundamental to advancing important clinical knowledge that can lead to more informed diagnosis and improved care for patients with Alzheimers disease and other dementias, said Dr. Connie Reininger, Navideas Senior Vice President and Chief Medical Officer.
Navideas commitment to advancing precision diagnostics encompasses our neuroimaging candidates NAV4694, in development for use as an aid in the diagnosis of Alzheimers disease and potentially Mild Cognitive Impairment; and NAV5001, which we are developing to aid in the evaluation of patients who may have dementia with Lewy Bodies, in addition to its benefits in the diagnosis of Parkinsons Disease, commented Dr. Mark Pykett, Chief Executive Officer of Navidea.
The Alzheimer's Imaging Consortium will consist of invited speakers, as well as oral and poster presentations from submitted abstracts. Leading imaging and non-imaging researchers from around the world will discuss topics such as:
- Early and differential diagnosis and the proposal for new criteria;
- Tracking progression and evaluating treatments;
- Asymptomatic stages of Alzheimer's and normal brain aging;
- Cognitive and basic neuroscientific studies: animal imaging, imaging and genetics;
- Multi-modality imaging studies and new imaging methods; and
- The latest developments on other dementias such as Lewy body disease and vascular diseases.
NAV4694 is a Fluorine-18 labeled precision radiopharmaceutical candidate intended for use in Positron Emission Tomography (PET) imaging and evaluation of patients with signs or symptoms of cognitive impairment such as Alzheimers disease (AD). NAV4694 binds to ²-amyloid deposits in the brain that can then be imaged in scans. ²-amyloid plaque pathology is widely used in the diagnosis of AD. The ability of NAV4694 imaging to display amyloid plaque pathology may enable earlier identification of AD and improve monitoring of disease progression and interpretation of brain scan images. Navidea has an ongoing NAV4694 Phase 2b trial in Mild Cognitive Impairment and a Phase 3 program for NAV4694 in AD.
Alzheimers disease (AD) is a progressive and fatal neurodegenerative disease which affects a persons memory and ability to learn, reason, communicate and carry out daily activities. Increasing age is the greatest risk factor for AD and there is no prevention or cure. The World Health Organization estimates that Alzheimers disease affects over 24 million people worldwide. Currently in the U.S. alone, there are over 5 million Alzheimers patients with estimates that by 2050, as many as 14 million Americans could have the disease according to the Alzheimers Association. Among the brain changes believed to contribute to the development of Alzheimers are the accumulation of the protein ²-amyloid outside nerve cells (neurons) in the brain and the accumulation of the protein tau inside neurons. Approximately 75 to 100 experimental technologies aimed at diagnosing, slowing or stopping the progression of Alzheimers are now in human clinical trials.
About Navidea Biopharmaceuticals Inc.
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Navidea is actively developing four radiopharmaceutical agent platforms Lymphoseek®, NAV4694, NAV5001 and RIGScanTM to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making and, ultimately, patient care. Navideas strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and advancing the Companys pipeline through selective acquisitions, global partnering and commercialization efforts. For more information, please visit www.navidea.com.
The Private Securities Litigation Reform Act of 1995 (the Act) provides a safe harbor for forward-looking statements made by or on behalf of the Company. Statements in this news release, which relate to other than strictly historical facts, such as statements about the Companys plans and strategies, expectations for future financial performance, new and existing products and technologies, anticipated clinical and regulatory pathways, and markets for the Companys products are forward-looking statements within the meaning of the Act. The words believe, expect, anticipate, estimate, project, and similar expressions identify forward-looking statements that speak only as of the date hereof. Investors are cautioned that such statements involve risks and uncertainties that could cause actual results to differ materially from historical or anticipated results due to many factors including, but not limited to, the Companys continuing operating losses, uncertainty of market acceptance of its products, reliance on third party manufacturers, accumulated deficit, future capital needs, uncertainty of capital funding, dependence on limited product line and distribution channels, competition, limited marketing and manufacturing experience, risks of development of new products, regulatory risks and other risks detailed in the Companys most recent Annual Report on Form 10-K and other Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements.
Navidea Biopharmaceuticals (NAVB)
Brent Larson, 614-822-2330
Executive VP & CFO
Stern Investor Relations, Inc.
Beth DelGiacco, 212-362-1200
Source: Navidea Biopharmaceuticals, Inc.Copyright Business Wire 2013